Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 8

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 8
---
 shares of our common stock, shares of our preferred stock, various series of debt securities and warrants to purchase any of such securities from time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:

| • |     | designation or classification; |

| • |     | aggregate principal amount or aggregate offering price; |

| • |     | maturity, if applicable; |

3

| • |     | original issue discount, if any; |

| • |     | rates and times of payment of interest or dividends, if any; |

| • |     | redemption, conversion, exchange or sinking fund terms, if any; |

| • |     | conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments              
 in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; |

| • |     | ranking, if applicable; |

| • |     | restrictive covenants, if any; |

| • |     | voting or other rights, if any; and |

| • |     | a discussion of material U.S. federal income tax considerations, if any. |

The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. We may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement:

| • |